ASH 2018: Better Early Molecular Response and relapse free survival in Newly Diagnosed Core Binding Factor Leukemia

Gautam Borthakur | | December 11, 2018

Föreläsare: Gautam Borthakur

Compared to idarubicin, GO when added to FLAG based frontline induction/consolidation regimen results in better early molecular responses and improved relapse free survival in CBF AML. Click and hear Gautam Borthakur present the new data.